Clearside - Suprachoroidal Space (SCS) Microinjector
Clearside’s proprietary SCS injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company’s unique platform is inherently flexible and intended to work with established medications, new formulations of medicines, as well as future innovations, that can be delivered via suprachoroidal administration.
Clearside has developed the only clinically tested product to obtain FDA approval for suprachoroidal drug delivery. Our proprietary SCS Microinjector® can be used to inject a wide variety of therapies designed to be delivered via suprachoroidal injection in order to flow to the back of the eye. The SCS Microinjector provides targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. Suprachoroidal injection enables the rapid dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye.
- Clinically tested in >1200 suprachoroidal Injections
- Injections performed across multiple retinal disorders
- Safety profile comparable to intravitreal injections
- XIPERE®: first approved therapeutic delivered into the suprachoroidal space